iCad (Nasdaq:ICAD) today announced plans to present new studies validating its AI-powered ProFound Breast Health Suite. ProFound helps to uncover hidden heart or vascular disease and predict a woman’s risk for developing breast cancer in the next 1-2 years. The platform can screen a single mammogram for two of the top causes of death for […]
iCad
iCad sells Xoft brachytherapy business to Elekta
iCad today announced it sold its Xoft Brachytherapy business line to Elekta for approximately $5.5 million. Elekta is taking over the business, effective immediately, and will make final payments to iCad no later than November 6, 2023. As part of the deal, Elekta will assume all liabilities, and employees will transfer with the business. The […]